4.7 Review

Transcription factor EB agonists from natural products for treating human diseases with impaired autophagy-lysosome pathway

Journal

CHINESE MEDICINE
Volume 15, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13020-020-00402-1

Keywords

TFEB; Autophagy; Autophagy-lysosome pathway; Natural products; TFEB agonists

Funding

  1. National Key R&D Program of China [2017YFC1703802]
  2. National Natural Science Foundation of China [U1801287, 81872842, 82073821]
  3. Natural Science Foundation of Guangdong Province [2020A1515011061]
  4. Science and Technology Planning Project of Guangdong Province [2020B1111110004, 2018B020207008]
  5. Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program [2017BT01Y036]

Ask authors/readers for more resources

Autophagy is a highly conserved degradation process for long-lived intracellular proteins and organelles mediated by lysosomes. Deficits in the autophagy-lysosome pathway (ALP) have been linked to a variety of human diseases, including neurodegenerative diseases, lysosomal storage disorders, and cancers. Transcription factor EB (TFEB) has been identified as a major regulator of autophagy and lysosomal biogenesis. Increasing evidence has demonstrated that TFEB activation can promote the clearance of toxic protein aggregates and regulate cellular metabolism. Traditional Chinese medicine (TCM)-derived natural products as important sources for drug discovery have been widely used for the treatment of various diseases associated with ALP dysfunction. Herein, we review (1) the regulation of TFEB and ALP; (2) TFEB and ALP dysregulation in human diseases; (3) TFEB activators from natural products and their potential uses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available